{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:57:43Z","timestamp":1792789063074,"version":"4.5.0"},"reference-count":131,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["18CSA34080399"],"award-info":[{"award-number":["18CSA34080399"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood institute","doi-asserted-by":"publisher","award":["1R01HL134892"],"award-info":[{"award-number":["1R01HL134892"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"RRM Charitable Fund","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Simard Fund","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Recent clinical trials have now firmly established that inflammation participates causally in human atherosclerosis. These observations point the way toward novel treatments that add to established therapies to help stem the growing global epidemic of cardiovascular disease. Fortunately, we now have a number of actionable targets whose clinical exploration will help achieve the goal of optimizing beneficial effects while avoiding undue interference with host defenses or other unwanted actions. This review aims to furnish the foundation for this quest by critical evaluation of the current state of anti-inflammatory interventions within close reach of clinical application, with a primary focus on innate immunity. In particular, this paper highlights the pathway from the inflammasome, through interleukin (IL)-1 to IL-6 supported by a promising body of pre-clinical, clinical, and human genetic data. This paper also considers the use of biomarkers to guide allocation of anti-inflammatory therapies as a step toward realizing the promise of precision medicine. The validation of decades of experimental work and association studies in humans by recent clinical investigations provides a strong impetus for further efforts to target inflammation in atherosclerosis to address the considerable risk that remains despite current therapies.<\/jats:p>","DOI":"10.3390\/cells10040951","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T13:58:04Z","timestamp":1618927084000},"page":"951","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":147,"title":["Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond"],"prefix":"10.3390","volume":"10","author":[{"given":"Peter","family":"Libby","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Gencer, S., Evans, B., van der Vorst, E., D\u00f6ring, Y., and Weber, C. (2021). Inflammatory Chemokines in Atherosclerosis. Cells, 10.","DOI":"10.3390\/cells10020226"},{"key":"ref_2","first-page":"179","article-title":"Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells","volume":"124","author":"Libby","year":"1986","journal-title":"Am. J. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1172\/JCI112732","article-title":"Inducible interleukin-1 gene expression in human vascular smooth muscle cells","volume":"78","author":"Libby","year":"1986","journal-title":"J. Clin. Investig."},{"key":"ref_4","unstructured":"Stein, O., Eisenberg, S., and Stein, Y. (1992). Possible roles of cytokines in atherogenesis. Atherosclerosis IX Tel Aviv, R&L Creative Communications."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/ATVBAHA.110.207415","article-title":"Recent Advances on the Role of Cytokines in Atherosclerosis","volume":"31","author":"Taleb","year":"2011","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-2929-0_2","article-title":"Cytokines and Immune Responses in Murine Atherosclerosis","volume":"1339","author":"Kusters","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1084\/jem.165.5.1316","article-title":"Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells","volume":"165","author":"Warner","year":"1987","journal-title":"J. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.4049\/jimmunol.139.6.1911","article-title":"Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells","volume":"139","author":"Warner","year":"1987","journal-title":"J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.1073\/pnas.81.24.7907","article-title":"Nucleotide sequence of human monocyte interleukin-1 precursor cDNA","volume":"81","author":"Auron","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.4049\/jimmunol.139.6.1902","article-title":"Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro","volume":"139","author":"Ikejima","year":"1987","journal-title":"J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The Interleukin-1 Family: Back to the Future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/eurheartj\/ehaa623","article-title":"COVID-19 is, in the end, an endothelial disease","volume":"41","author":"Libby","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e0178","DOI":"10.1097\/CCE.0000000000000178","article-title":"Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019","volume":"2","author":"Buckley","year":"2020","journal-title":"Crit. Care Explor."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tcm.2020.10.005","article-title":"COVID-19\u2014A vascular disease","volume":"31","author":"Siddiqi","year":"2021","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/344633a0","article-title":"Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein [see comments]","volume":"344","author":"Falus","year":"1990","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1172\/JCI115453","article-title":"Interleukin 1 receptor antagonist","volume":"88","author":"Arend","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra Therapy for Non-cancer Inflammatory Diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MOL.0000000000000382","article-title":"Inflammation, remodeling, and other factors affecting HDL cholesterol efflux","volume":"28","author":"Ronsein","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A Test in Context: High-Sensitivity C-Reactive Protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_22","first-page":"251","article-title":"Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme","volume":"147","author":"Geng","year":"1995","journal-title":"Am. J. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19569","DOI":"10.1074\/jbc.272.31.19569","article-title":"Ligation of CD40 activates interleukin-1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin-1 beta","volume":"272","author":"Schoenbeck","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.coi.2007.09.002","article-title":"The inflammasome: A danger sensing complex triggering innate immunity","volume":"19","author":"Dostert","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"ref_25","first-page":"1357","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCULATIONAHA.113.004390","article-title":"Atheroprone flow activation of the sterol regulatory element binding protein 2 and nod-like receptor protein 3 inflammasome mediates focal atherosclerosis","volume":"128","author":"Abe","year":"2013","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCRESAHA.115.304437","article-title":"Moderate hypoxia potentiates interleukin-1beta production in activated human macrophages","volume":"115","author":"Folco","year":"2014","journal-title":"Circ. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Takahashi, M. (2021). NLRP3 inflammasome as a key driver of vascular disease. Cardiovasc. Res.","DOI":"10.1093\/cvr\/cvab010"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41590-019-0548-1","article-title":"Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation","volume":"21","author":"Zewinger","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cmet.2017.06.018","article-title":"Inflammasomes on the Crossroads of Innate Immune Recognition and Metabolic Control","volume":"26","author":"Prochnicki","year":"2017","journal-title":"Cell Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/FJC.0000000000000701","article-title":"Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes","volume":"74","author":"Buckley","year":"2019","journal-title":"J. Cardiovasc. Pharmcol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jacc.2014.11.039","article-title":"Cholesterol Crystals Associate with Coronary Plaque Vulnerability In Vivo","volume":"65","author":"Kataoka","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Schunk, S.J., E Kleber, M., M\u00e4rz, W., Pang, S., Zewinger, S., Triem, S., Ege, P., Reichert, M.C., Krawczyk, M., and Weber, S.N. (2021). Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur. Heart J.","DOI":"10.1093\/eurheartj\/ehab107"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Fidler, T.P., Xue, C., Yalcinkaya, M., Hardaway, B., Abramowicz, S., Xiao, T., Liu, W., Thomas, D.G., Hajebrahimi, M.A., and Pircher, J. (2021). The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nat. Cell Biol., 1\u20136.","DOI":"10.1038\/s41586-021-03341-5"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/FJC.0000000000000658","article-title":"The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse","volume":"73","author":"Toldo","year":"2019","journal-title":"J. Cardiovasc. Pharmcol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780190315","article-title":"Effect of prophylactic colchicine therapy on leukocyte function in patients with familial mediterranean fever","volume":"19","author":"Dinarello","year":"1976","journal-title":"Arthritis Rheum."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa1208536","article-title":"A Randomized Trial of Colchicine for Acute Pericarditis","volume":"369","author":"Imazio","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_39","first-page":"237","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.120.050560","article-title":"Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy","volume":"142","author":"Opstal","year":"2020","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: The MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0014-4827(92)90381-H","article-title":"Functional significance of human vascular smooth muscle cell-derived interleukin1 in paracrine and autocrine regulation pathways","volume":"198","author":"Loppnow","year":"1992","journal-title":"Exp. Cell Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2006.11.026","article-title":"Differential role and tissue specificity of interleukin-1\u03b1 gene expression in atherogenesis and lipid metabolism","volume":"195","author":"Kamari","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbrc.2011.01.008","article-title":"Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1\u03b1","volume":"405","author":"Kamari","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/ni.2704","article-title":"Fatty acid\u2013induced mitochondrial uncoupling elicits inflammasome-independent IL-1\u03b1 and sterile vascular inflammation in atherosclerosis","volume":"14","author":"Freigang","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1161\/ATVBAHA.118.311150","article-title":"Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1\u03b1 and Cathepsin G","volume":"38","author":"Folco","year":"2018","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/eurheartj\/ehz008","article-title":"Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis","volume":"40","author":"Vromman","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/CIRCULATIONAHA.120.046301","article-title":"Postischemic Administration of IL-1\u03b1 Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke","volume":"142","author":"Liberale","year":"2020","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in Inflammation, Immunity, and Disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Cell Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2018.02.062","article-title":"All roads lead to IL-6, A central hub of cardiometabolic signaling","volume":"259","author":"Libby","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6, designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/01.ATV.19.10.2364","article-title":"Interleukin-6 Exacerbates Early Atherosclerosis in Mice","volume":"19","author":"Huber","year":"1999","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1161\/01.CIR.0000148135.08582.97","article-title":"Impact of Interleukin-6 on Plaque Development and Morphology in Experimental Atherosclerosis","volume":"110","author":"Schieffer","year":"2004","journal-title":"Circulation"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.atherosclerosis.2007.02.023","article-title":"Atheroprotective role of interleukin-6 in diet- and\/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model","volume":"197","author":"Madan","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/ATVBAHA.111.229435","article-title":"Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice","volume":"32","author":"Schuett","year":"2012","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1084\/jem.20070120","article-title":"Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man","volume":"204","author":"Luchtefeld","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1160\/TH09-05-0297","article-title":"How much is too much? Interleukin-6 and its signalling in atherosclerosis","volume":"102","author":"Schuett","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_69","first-page":"14","article-title":"Interleukin-6 in atherosclerosis: Atherogenic or atheroprotective?","volume":"12","author":"Reiss","year":"2017","journal-title":"Clin. Lipidol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Kim, K.-W., Ivanov, S., and Williams, J.W. (2020). Monocyte Recruitment, Specification, and Function in Atherosclerosis. Cells, 10.","DOI":"10.3390\/cells10010015"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis","volume":"379","author":"Holmes","year":"2012","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/cvr\/cvy233","article-title":"Interleukin-6 trans-signalling and risk of future cardiovascular events: A new avenue for atheroprotection?","volume":"115","author":"Ferrante","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: Further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/eurheartj\/ehaa160","article-title":"Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: Secondary analyses from the Cardiovascular Inflammation Reduction Trial","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1161\/01.CIR.99.16.2079","article-title":"Increasing Levels of Interleukin (IL)-1Ra and IL-6 During the First 2 Days of Hospitalization in Unstable Angina Are Associated with Increased Risk of In-Hospital Coronary Events","volume":"99","author":"Biasucci","year":"1999","journal-title":"Circulation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1001\/jama.286.17.2107","article-title":"Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or noninvasive strategy","volume":"286","author":"Lindmark","year":"2001","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e005077","DOI":"10.1161\/JAHA.116.005077","article-title":"Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial","volume":"6","author":"Held","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00392-018-1387-z","article-title":"Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction","volume":"108","author":"Groot","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.atherosclerosis.2015.04.014","article-title":"Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction","volume":"240","author":"Golabkesh","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/cvr\/cvy191","article-title":"Interleukin 6 trans-signalling and risk of future cardiovascular events","volume":"115","author":"Ziegler","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1161\/01.ATV.19.7.1695","article-title":"Plasma Concentrations of Interleukin-6 and Abdominal Aortic Diameter Among Subjects Without Aortic Dilatation","volume":"19","author":"Rohde","year":"1999","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e002413","DOI":"10.1161\/CIRCGEN.118.002413","article-title":"Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates","volume":"12","author":"Paige","year":"2019","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: A double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2018.04.136","article-title":"Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1beta in non-ST-elevation myocardial infarction","volume":"271","author":"Kleveland","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e001108","DOI":"10.1136\/openhrt-2019-001108","article-title":"Rationale for the ASSAIL-MI-trial: A randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)","volume":"6","author":"Anstensrud","year":"2019","journal-title":"Open. Heart"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/ATVBAHA.119.311998","article-title":"Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk","volume":"39","author":"Libby","year":"2019","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/scientificamerican0588-59","article-title":"Tumor Necrosis Factor","volume":"258","author":"Old","year":"1988","journal-title":"Sci. Am."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/320584a0","article-title":"Cachectin and tumour necrosis factor as two sides of the same biological coin","volume":"320","author":"Beutler","year":"1986","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants\u2014Past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.canlet.2012.10.014","article-title":"Tumor necrosis factor","volume":"328","author":"Chu","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11886-018-1067-7","article-title":"Tumor Necrosis Factor-alpha in Heart Failure: An Updated Review","volume":"20","author":"Schumacher","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","article-title":"Innate immunity and the failing heart: The cytokine hypothesis revisited","volume":"116","author":"Mann","year":"2015","journal-title":"Circ. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.acvd.2019.11.001","article-title":"Antibody-based immunotherapy targeting cytokines and atherothrombotic cardiovascular diseases","volume":"113","author":"Libby","year":"2020","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/hc3901.096721","article-title":"Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability","volume":"104","author":"Mallat","year":"2001","journal-title":"Circulation"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1084\/jem.20011022","article-title":"Expression of Interleukin (IL)-18 and Functional IL-18 Receptor on Human Vascular Endothelial Cells, Smooth Muscle Cells, and Macrophages: Implication for atherogenesis","volume":"195","author":"Gerdes","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nm.3890","article-title":"Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter","volume":"21","author":"Wang","year":"2015","journal-title":"Nat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/ni.2072","article-title":"NF-kappaB is 25","volume":"12","author":"Baltimore","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","article-title":"NF-\u03baB directs dynamic super enhancer formation in inflammation and atherogenesis","volume":"56","author":"Brown","year":"2014","journal-title":"Mol. Cell."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.2174\/138161212803530763","article-title":"NF-kappaB as a target for modulating inflammatory responses","volume":"18","author":"Gasparini","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jacc.2018.12.083","article-title":"Targeting the Immune System in Atherosclerosis: JACC State-of-the-Art Review","volume":"73","author":"Zhao","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer, S., and Zernecke, A. (2021). CD8+ T Cells in Atherosclerosis. Cells, 10.","DOI":"10.3390\/cells10010037"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2014.10.018","article-title":"Vaccine for Atherosclerosis","volume":"64","author":"Shah","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1161\/CIRCRESAHA.120.315942","article-title":"Vaccination Strategies and Immune Modulation of Atherosclerosis","volume":"126","author":"Nilsson","year":"2020","journal-title":"Circ. Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Nettersheim, F.S., De Vore, L., and Winkels, H. (2020). Vaccination in Atherosclerosis. Cells, 9.","DOI":"10.3390\/cells9122560"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Ma, S., Mussbacher, M., and Galkina, E. (2021). Functional Role of B Cells in Atherosclerosis. Cells, 10.","DOI":"10.3390\/cells10020270"},{"key":"ref_110","first-page":"A19","article-title":"Rituximab in Patients with Acute ST-elevation Myocardial Infarction (RITA-MI): An Experimental Medicine Safety Study","volume":"106","author":"Zhao","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Ali, A.J., Makings, J., and Ley, K. (2020). Regulatory T Cell Stability and Plasticity in Atherosclerosis. Cells, 9.","DOI":"10.3390\/cells9122665"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e022452","DOI":"10.1136\/bmjopen-2018-022452","article-title":"Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): Protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I\/II clinical trial","volume":"8","author":"Zhao","year":"2018","journal-title":"BMJ Open"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.atherosclerosis.2018.06.451","article-title":"HSP27 immunization attenuates atherogenesis by markedly reducing plasma PCSK9 and cholesterol levels","volume":"275","author":"Shi","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"Braunwald","year":"2014","journal-title":"JAMA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","author":"White","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.2016.3609","article-title":"Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial","volume":"315","author":"Glaser","year":"2016","journal-title":"JAMA"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijcard.2015.02.072","article-title":"High dose and long-term statin therapy accelerate coronary artery calcification","volume":"184","author":"Henein","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2015.01.036","article-title":"Impact of Statins on Serial Coronary Calcification During Atheroma Progression and Regression","volume":"65","author":"Puri","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"ref_122","first-page":"A15111","article-title":"TET2-Driven Clonal Hematopoiesis Predicts Enhanced Response to Canakinumab in the CANTOS Trial: An Exploratory Analysis","volume":"138","author":"Madar","year":"2018","journal-title":"Circulation"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/CIRCRESAHA.118.313283","article-title":"Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 V617F Mice","volume":"123","author":"Wang","year":"2018","journal-title":"Circ. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1161\/CIRCRESAHA.114.302699","article-title":"Inflammation and its Resolution as Determinants of Acute Coronary Syndromes","volume":"114","author":"Libby","year":"2014","journal-title":"Circ. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.ajpath.2017.01.018","article-title":"Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy","volume":"187","author":"Fredman","year":"2017","journal-title":"Am. J. Pathol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1096\/fj.201601222R","article-title":"Treating inflammation and infection in the 21st century: New hints from decoding resolution mediators and mechanisms","volume":"31","author":"Serhan","year":"2017","journal-title":"FASEB J."},{"key":"ref_127","unstructured":"Bhatt, D.L. (2020). Drugs Targeting Inflammation. Opie\u2019s Cardiovascular Drugs: A Companion to Braunwald\u2019s Heart Disease, Elsevier. [9th ed.]."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1172\/JCI97943","article-title":"Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"E Strandberg, T., Libby, P., and Kovanen, P.T. (2020). A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: A false dichotomy?. Eur. Heart J. Cardiovasc. Pharmacother.","DOI":"10.1093\/ehjcvp\/pvaa131"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.117.030484","article-title":"Inflammation and Atherosclerosis\u2014The End of a Controversy","volume":"136","author":"Hansson","year":"2017","journal-title":"Circulation"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/clinchem\/hvaa275","article-title":"Inflammation in Atherosclerosis\u2014No Longer a Theory","volume":"67","author":"Libby","year":"2021","journal-title":"Clin. Chem."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/4\/951\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:50:09Z","timestamp":1760161809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/4\/951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":131,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["cells10040951"],"URL":"https:\/\/doi.org\/10.3390\/cells10040951","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}